My Adelaide-based team is focussed on development of vaccines and drugs against pathogens that pose major public health threats including Covid-19, MERS CoV, pandemic influenza, Japanese encephalitis, and Ebola, amongst many others. The team employs advanced technologies including artificial intelligence to accelerate vaccine development. The team was successful in obtaining regulatory approved for its Covid-19 protein-based vaccine in early October 2021, making it the first recombinant full spike protein in the world to reach this milestone. The team had to overcome numerous obstacles, including major supply chain disruptions and local lockdowns, on top of the usual challenges of optimising protein expression, purification and characterisation. Nevertheless, the entire process from initial vaccine design to regulatory approval was completed in just 18 months, making this the record for the fastest development through to approval of a recombinant protein vaccine. Covax19/Spikogen has many promising features including high yield and low cost, temperature stability, strong T and B cell memory, broad cross-protection and high tolerability and safety with 6 million doses administered to date.